For citations:
Nedogoda S.V., Ledyaeva A.A., Salasyuk A.S., Chumachek E.V., Tsoma V.V., Lutova V.O., Popova E.A., Vlasov D.S., Bychkova O.I., Labaznikova V.V., Evdokimov K.S. Blood pressure control, target organ protection and metabolic disorders control using a fixed combination of azilsartan medoxomil + chlorthalidone in hypertensive patients survived after severe and extremely severe COVID-19. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2021;27(6):642-652. (In Russ.) https://doi.org/10.18705/1607-419X-2021-27-6-642-652